Category:

Europe wants to be master of its own destiny in producing essential drugs and finding COVID-19 treatments, but it’s got a problem. It relies on the United States for a critical ingredient: blood plasma...As global mistrust deepens, European Union officials are casting around for ways to reduce the bloc’s dependence on American plasma...now widely applied in COVID-19 experimental therapies...The coronavirus crisis should push authorities to overhaul Europe’s blood donation system...The United States’ steadier plasma supplies are partly due to its system of paying people to donate blood used to develop medicines. In most European countries, donations are unpaid because of safety and ethical reasons...The PPTA (Plasma Protein Therapeutics Association ) drugmakers body sees a strategy based on unpaid blood donations as counterproductive. It pointed to Germany, the largest collector of plasma in Europe, as one of the few countries that compensate blood donors...READ MORE

The U.S. biopharmaceutical industry depends on reliable intellectual property protections to promote the development of new treatments and cures for patients. Strong IP protections are especially important as innovators work around the clock making substantial investments at risk to develop solutions to help prevent infection and treat those with COVID-19...many of the existing medicines and investigational medicines in clinical trials for COVID-19 exist today because of IP and other incentives that drove their initial research...Strong and reliable IP protections support America’s robust innovation ecosystem by promoting innovation and affordability for patients who rely on new treatments and cures...READ MORE

...the first large, high-quality study to test it in people in close contact with someone with the disease...Results published...by the New England Journal of Medicine show that hydroxychloroquine was no better than placebo pills at preventing illness from the coronavirus...The study enrolled people through the Internet and social media, relying on them to report their own symptoms rather than having them tracked in a formal way by doctors. Participants were not all tested for the coronavirus but were diagnosed as COVID-19 cases based on symptoms in many cases. And not all took their medicines as directed...READ MORE

Biotech and pharma companies are focused these days on delivering drugs and vaccines to fight the pandemic, but just a few months ago, they were recounting their 2019 accomplishments...While the world has changed for everyone—and drugmakers expect some financial pain this year—many enjoyed a productive year last year, with sales increases, new drug launches, M&A deals and plenty of clinical data. Those companies, and some with less stellar résumés, rewarded their CEOs handsomely for that work...Generally, a biopharma CEO's compensation derives from progress on several fronts, including R&D developments, as well as the usual revenue and stock price metrics...this year's roundup of biopharma’s best-paid CEOs...READ MORE

• Martine Rothblatt (United Therapeutics)
• Daniel O'Day (Gilead Sciences)
• Kenneth Frazier (Merck & Co.)
• Alex Gorsky (Johnson & Johnson)
• Richard Gonzalez (AbbVie)
• David Ricks (Eli Lilly)
• Robert Bradway (Amgen)
• Ludwig Hantson (Alexion Pharmaceuticals)
• Jeffrey Leiden (Vertex Pharmaceuticals)
• Giovanni Caforio (Bristol Myers Squibb)
• Heather Bresch (Mylan)
• Pascal Soriot (AstraZeneca)
• Michel Vounatsos (Biogen)
• Albert Bourla (Pfizer)

Pharmacists, pharmacy technicians, and other pharmacy staff felt overtaxed even before the coronavirus disease 2019 pandemic hit, according to findings from the 2019 National Pharmacist Workforce Study. The survey results showed that 69% of full-time pharmacists reported that their workload “increased” or “greatly increased” compared with the prior year...Although the profession is much more racially and gender diverse than in previous years, pharmacy staff reported age, race, and gender discrimination...Among full-time, actively practicing pharmacists, 71% rated their workload level at their primary place of employment as “high” or “excessively high” in 2019, compared with 66% and 68% of full-time pharmacists in 2014 and 2009, respectively...READ MORE

The coronavirus pandemic hasn't deterred investors of Atlas Venture, a biotechnology-focused venture capital firm. On Friday, Atlas announced its latest fund, which opened at the end of March, had closed with a higher-than-expected yield of $400 million...Atlas initially wanted to bring in $350 million from the fund...But when the firm went out to fundraise, it was met with more than $1 billion in demand, which then pushed the fund toward a cap of $400 million...the fresh money will be put into about 15 companies, and that his firm remains interested in areas such as targeted cancer drugs, gene therapy and the central nervous system...The pandemic's impact on biotech stocks was fleeting compared to the larger market. Venture-backed drug companies have also continued to go public, which has kept firms and their investors optimistic about their ability to earn returns...While there are enormous parts of the broader economy...that have been really adversely affected by the COVID-related lockdowns, biotech is doing very well...The fund flows are very strong by any measure...READ MORE

With the COVID-19 pandemic shining a spotlight on the global pharmaceutical supply chain, U.S. legislators have put forward a raft of legislation that would seek to "onshore" drug manufacturing at the expense of major producers abroad...Guess who's wary of that proposal? Big Pharma...the White House is reportedly working on a "Buy American" executive order that would require government agencies to purchase American-made medical products, and that order could eventually include pharmaceuticals...the Pharmaceutical Research and Manufacturers of America...has pushed back against Congressional support for a supply chain shake-up...Manufacturing stateside would likely cost a princely sum compared with the cheaper wages and lower costs abroad, and would upset the balance of pharma's global supply chain..."While we support efforts to foster more manufacturing in the United States, moving all manufacturing here is impractical and likely not feasible," a PhRMA spokesperson said in an email. "Policymakers must take a long-term, more holistic look at global pharmaceutical manufacturing supply chains before jumping to rash proposals that may cause significant disruptions to the U.S. supply of medicines."...READ MORE

The Bureau of Labor Statistics recently released its employment data for 2019...our annual Drug Channels analysis of pharmacist salaries and employment...Average base salaries were about $125,000, though there was substantial variation across practice settings...Total pharmacist employment grew in 2019...the share of pharmacists who work at hospitals reached a new high...the number of pharmacists working in retail settings decreased. The challenges facing the retail pharmacy industry...are now showing up in the employment data...READ MORE

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts to secure supplies should any immunizations prove safe and effective. Right on the heels of news that the U.S. has picked vaccine finalists to fast-track, Europe is considering negotiations with pharmaceutical companies for early acces..The European Union has asked member countries for the power to negotiate development and access deals with drugmakers.. if the mandate were approved, Europe would base its program on the U.S.’ Biomedical Advanced Research and Development Authority...READ MORE

The U.S. government...entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine...As drugmakers capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted,” Department of Health and Human Services Secretary Alex Azar said in a statement...The HHS task order with Emergent falls under an existing contract with the Biomedical Advanced Research and Development Authority...Under the contract, Emergent will commit its manufacturing facilities, valued at $542.7 million, to produce COVID-19 vaccine candidates through 2021...READ MORE